Tracy H. Erkkila

Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation.

Los Alamos National Laboratory operates as a multidisciplinary institution. It offers services in science, engineering, earth science, chemistry, mathematics, physics, and space science. The company was founded in 1943 and is headquartered in Los Alamos, NM.

Rosetta Inpharmatics LLC designed and implemented DNA microarray gene expression systems. The company provided software for use in informational genomics. The company was founded in may 29, 2009 and was headquartered in Seattle, WA.

Association for Laboratory Automation operated laboratory automation. The company was headquartered in Geneva, IL.